A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Dual PPARα/γ can improve both metabolic effects and minimized the side effects caused by either PPARα or PPARγ agonist. The PRESS V study was aimed to evaluate the safety, tolerability, and efficacy of saroglitazar 2 mg and 4 mg capsules (Lipaglyn™; Zydus Code: ZYH1) as compared to high dose pioglit...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai, Vikas, Paneerselvam, A, Mukhopadhyay, Satinath, Bhansali, Anil, Kamath, Dinesh, Shankar, V, Gambhire, Dhiraj, Jani, Rajendrakumar H., Joshi, Shashank, Patel, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390522/
https://www.ncbi.nlm.nih.gov/pubmed/24876549
http://dx.doi.org/10.1177/1932296813518680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390522/
https://www.ncbi.nlm.nih.gov/pubmed/24876549
http://dx.doi.org/10.1177/1932296813518680

Ejemplares similares